Carl Zeiss Meditec AG
XETRA:AFX
Carl Zeiss Meditec AG
Cash & Cash Equivalents
Carl Zeiss Meditec AG
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Carl Zeiss Meditec AG
XETRA:AFX
|
Cash & Cash Equivalents
€20.3m
|
CAGR 3-Years
40%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
8%
|
|
|
Stratec SE
XETRA:SBS
|
Cash & Cash Equivalents
€33.1m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
15%
|
CAGR 10-Years
0%
|
|
|
Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
|
Cash & Cash Equivalents
€97.6m
|
CAGR 3-Years
2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
17%
|
|
|
Siemens Healthineers AG
XETRA:SHL
|
Cash & Cash Equivalents
€2.8B
|
CAGR 3-Years
28%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Draegerwerk AG & Co KGaA
XETRA:DRW8
|
Cash & Cash Equivalents
€179.8m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
3%
|
CAGR 10-Years
0%
|
|
|
Sartorius AG
XETRA:SRT
|
Cash & Cash Equivalents
€813.4m
|
CAGR 3-Years
33%
|
CAGR 5-Years
72%
|
CAGR 10-Years
35%
|
|
Carl Zeiss Meditec AG
Glance View
Carl Zeiss Meditec AG stands as a beacon in the realm of medical technology, carving a niche through its innovative solutions in ophthalmology and microsurgery. Rooted in the prestigious legacy of the Zeiss Group, this company seamlessly fuses cutting-edge technology with practical medical applications. Its headquarters in Jena, Germany, serve as the crucible for pioneering research and development endeavors, channeling expertise into products that enhance both diagnostic and surgical capabilities. The heart of its operations revolves around creating technological marvels such as optical coherence tomography (OCT) instruments and surgical microscopes, which bring precision and enhanced clarity to the medical field. Through a well-executed blend of R&D and strategic acquisitions, Carl Zeiss Meditec consistently remains at the forefront of medical innovation, ensuring it meets the ever-evolving needs of the healthcare sector. Financially, the company thrives by selling its sophisticated medical devices directly to healthcare professionals, hospitals, and clinics worldwide. Rather than merely creating instruments, Carl Zeiss Meditec's business model is deeply entwined with providing comprehensive workflow solutions and service support, ensuring that medical practitioners extract maximum utility from their investments. By offering not just products but also extensive after-sales service and maintenance, the company builds sustained relationships with its clients, fostering a cycle of trust and repeat business. In addition, its engagement in training and support services enhances user competencies, ensuring the seamless integration of its technology into everyday medical practice and underscoring its commitment to elevating healthcare standards globally. Through this multifaceted approach, Carl Zeiss Meditec solidifies its position as an indispensable ally in the medical community, both as a supplier of state-of-the-art equipment and as a provider of essential healthcare solutions.
See Also
What is Carl Zeiss Meditec AG's Cash & Cash Equivalents?
Cash & Cash Equivalents
20.3m
EUR
Based on the financial report for Dec 31, 2024, Carl Zeiss Meditec AG's Cash & Cash Equivalents amounts to 20.3m EUR.
What is Carl Zeiss Meditec AG's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
8%
Over the last year, the Cash & Cash Equivalents growth was 91%. The average annual Cash & Cash Equivalents growth rates for Carl Zeiss Meditec AG have been 40% over the past three years , -2% over the past five years , and 8% over the past ten years .
You don't have any saved screeners yet